Please login to the form below

enzalutamide

This page shows the latest enzalutamide news and features for those working in and with pharma, biotech and healthcare.

Astellas’ Xtandi (enzalutamide).

Givlaari, Rybelsus lead crowded CHMP recommendations

Nubeqa will go head-to-head in the non-metastatic castration-resistant prostate cancer market with J&J’s Erleada (apalutamide), as well as Pfizer/Astellas’ Xtandi (enzalutamide).
J&J gets EMA nod for wider use of Erleada in prostate cancer

Erleada can now be used for mCSPC patients in combination with ADT in Europe ahead of Xtandi (enzalutamide), which was approved for this indication in December in the US but still
Clovis leapfrogs PARP rivals, filing Rubraca for prostate cancer

Johnson &Johnson’s Zytiga (abiraterone) or Pfizer’s Xtandi (enzalutamide).
Pfizer raises forecast following growth of biopharma business

Pfizer CEO Albert Bourla. Pfizer’s prostate cancer therapy Xtandi (enzalutamide) also grew in alliance revenues by 25% to $225m.
Lynparza scores another positive phase 3 prostate cancer study

Zytiga (abiraterone acetate) or Pfizer’s Xtandi (enzalutamide).

More from news
Approximately 12 fully matching, plus 57 partially matching documents found.

Cost containment and the German market

The main sales drivers are biopharmaceutical medicines like the monoclonal antibody adalimumab, TNF-alpha inhibitor etanercept as well as the oncologic drugs imatinib and enzalutamide.
Deal Watch May 2016

The prize of course is the one marketed product in Medivation's portfolio, Xtandi [enzalutamide for the treatment of advanced prostate cancer] with sales estimated to reach $1.5bn and already
Astellas: Ten years young

Its efforts to date in oncology have seen it form a prostate cancer franchise on the back of Eligard (leuprolide acetate) and more recently Xtandi (enzalutamide).

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Dendreon appoints new R&D lead

Joining from Astellas Pharma, Dr Brown most recently served as senior medical director of oncology, where he led US medical strategy for the prostate cancer drug Xtandi (enzalutamide).
Astellas promotes John Demaree

Demaree was promoted from his position as executive director of oncology marketing, where he oversaw the launch of prostate cancer drug Xtandi (enzalutamide) and promotion of lung cancer therapy Tarceva (erlotinib).
Astellas poaches new oncology head from Takeda

She will now lead Astellas' efforts in cancer, which include prostate cancer drug Xtandi (enzalutamide) and Tarveca (erlotinib) – a lung cancer drug co-marketed by Roche.

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Add my company

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

InSite Mapping™ - a Novel Tool for Insight-gathering and Patient Journey Mapping: Learn how a client engaged 18 rheumatologist advisors over 6 months to create a patient journey map for SLE....
Alone we can do so little, together we can do so much: Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
7 important considerations for creating an inclusive clinical trial website: You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...